Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is focusing on optimizing its product structure and enhancing brand development through a combination of its main brand products and new product innovations [6] - The company aims to expand its new business and retail channels to meet diverse consumer needs, implementing a fresh delivery service in 24 cities [6] - The company is committed to high-quality development and exploring new growth areas through acquisitions and partnerships in non-beer businesses [8] Summary by Sections Basic Information - Latest closing price is 71.97 yuan - 12-month A-share price range is between 53.96 and 83.41 yuan - Total share capital is 1,364.20 million shares - Circulating market value is 98.174 billion yuan [2] Financial Forecasts - Expected revenue for 2025 is 334.67 billion yuan, with a growth rate of 4.14% - Expected net profit for 2025 is 48.18 billion yuan, with a growth rate of 10.88% - Corresponding PE ratios are projected at 20x for 2025 [8][11] Business Strategy - The company is implementing a "1+1+1+2+N" product strategy to strengthen its main products while fostering new product development [6] - The company is actively exploring the integration of new businesses, including the acquisition of a traditional yellow wine company [7] - The company is enhancing its brand visibility and quality through innovative marketing strategies and consumer engagement [8]

公司研究 证 券 研 究 报 告 思看科技（688583）深度研究报告 强推（首次） 从平面到立体，商业级蓝海启航，工业级技 术筑基 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 333 | 421 | 534 | 677 | | 同比增速(%) | 22.4% | 26.5% | 26.9% | 26.8% | | 归母净利润(百万) | 121 | 144 | 173 | 209 | | 同比增速(%) | 5.5% | 19.6% | 19.8% | 20.8% | | 每股盈利(元) | 1.77 | 2.12 | 2.54 | 3.07 | | 市盈率(倍) | 60 | 50 | 42 | 35 | | 市净率(倍) | 11.5 | 9.6 | 5.3 | 4.8 | 资料来源：公司公告，华创证券预测 注：股价为 2025 年 5 月 23 日收盘价 仪器仪表Ⅲ 2025 年 05 月 24 日 | 目标价：148.35 ...

新能源业务快速成长，持续聚焦双轮驱动 战略 核心观点 盈利预测与投资建议 ⚫ 我们预测公司 25-27 年每股收益分别为 1.57、2.15、2.71 元（原 25-26 年预测分别 为 1.69、2.09 元，主要调整了营业收入、毛利率和费用率），根据可比公司 25 年 21 倍 PE 估值水平，对应目标价 32.97 元，维持买入评级。 风险提示 | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现 | 2.74 | 16.04 | -13.79 | 80.83 | | 相对表现 | 2.92 | 13.52 | -11.37 | 74.23 | | 沪深 300 | -0.18 | 2.52 | -2.42 | 6.6 | | 蒯剑 | 021-63325888*8514 | | --- | --- | | | kuaijian@orientsec.com.cn | | | 执业证书编号：S0860514050005 | | | 香港证监会牌照：BPT856 | | 韩潇锐 | hanxiaorui@orientsec.c ...

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 33.63 CNY [1][5] Core Views - The company is expected to benefit from the AI industry trends and is actively upgrading its production capacity to meet the growing demand for high-end HDI and SLP products [4][9] - The revenue for 2024 is projected to be 35.14 billion CNY, representing a year-on-year growth of 9.6%, while the net profit attributable to the parent company is expected to reach 3.62 billion CNY, a growth of 10.1% [9] - The company is focusing on expanding its market share in the AI edge PCB market and has seen significant growth in its automotive and server PCB segments [9] Financial Forecasts - The company’s earnings per share (EPS) are forecasted to be 1.77 CNY, 2.15 CNY, and 2.44 CNY for the years 2025, 2026, and 2027 respectively [5][13] - Revenue is expected to grow from 32.07 billion CNY in 2023 to 50.54 billion CNY by 2027, with a compound annual growth rate (CAGR) of approximately 12.9% [7] - The gross margin is projected to improve slightly from 21.3% in 2023 to 22.4% in 2027 [7] Business Segments - The company’s communication PCB business is expected to generate 24.24 billion CNY in revenue in 2024, a growth of 3.08%, while the consumer electronics and computer PCB business is projected to reach 9.75 billion CNY, growing by 22.3% [9] - The automotive and server PCB segments have shown substantial growth, with a revenue increase of 90.34% in 2024, reaching 1.025 billion CNY [9] Capital Expenditure - The company plans to invest 5 billion CNY in capital expenditures in 2025 to support its production capacity upgrades and global expansion [9]

Investment Rating - The report maintains a "Buy" rating for the company [6][2]. Core Views - The company's Q1 2025 performance was impacted by a slower-than-expected consumer recovery and high expense ratios, but it is now considered to have investment value. Projected net profits for 2025-2027 are estimated at 480 million, 530 million, and 610 million yuan, with corresponding PE ratios of 11, 10, and 9 times [2][4]. Summary by Sections Revenue Performance - In Q1 2025, the company reported revenue, net profit attributable to the parent, and net profit excluding non-recurring items of 1.3 billion, 170 million, and 160 million yuan, respectively, reflecting year-on-year declines of 4%, 32%, and 30% [4]. Profitability - The gross margin remained stable with a year-on-year increase of 0.1 percentage points. However, the expense ratio increased by 5.8 percentage points year-on-year, driven by higher sales, management, and financial expenses. The net profit margin decreased by 5.4 percentage points to 13.1% [4][2]. Operational Efficiency - Inventory increased by 3.5% year-on-year but decreased by 8.2% quarter-on-quarter, totaling 1.11 billion yuan. The cash flow from operating activities saw a significant increase of 353% year-on-year, reaching 79 million yuan, mainly due to improved cash collection and reduced procurement payments [4][2]. Future Outlook - The report suggests that once the negative impacts of the consumer recovery and high expense ratios dissipate, the company will present investment opportunities. The projected net profits for 2025-2027 indicate a positive growth trajectory [2][4].

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected relative increase of over 15% compared to the CSI 300 index in the next six months [9]. Core Insights - The company has shown rapid growth in its pig farming business, with a significant increase in the number of pigs sold and continuous optimization in cost management [3][4]. - The revenue for 2024 is projected to be CNY 5.584 billion, representing a year-on-year growth of 43.51%, with a net profit of CNY 687 million, reflecting a substantial increase of 271.16% [3][6]. - The company is recognized as a regional leader in the pig farming industry, with a flexible operating model and strong cost management capabilities [5]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of CNY 5.584 billion, with a net profit of CNY 687 million, and an EPS of CNY 1.31 [3][6]. - For Q1 2025, the company reported a revenue of CNY 1.471 billion, with a net profit of CNY 22.8 million, marking a year-on-year increase of 6510.85% [3]. Business Segments - The pig farming segment generated CNY 3.797 billion in revenue in 2024, up 81.53% year-on-year, with a gross margin of 23.42% [3]. - The slaughtering and meat products segment achieved revenue of CNY 1.386 billion in 2024, a 20.89% increase, with a gross margin of 15.52% [4]. Profitability Forecast - The company is expected to have a net profit of CNY 762 million in 2025 and CNY 836 million in 2026, with corresponding PE ratios of 11.15x and 10.17x [5][6]. - The projected revenue growth rates for the next few years are 34.13% for 2025 and 23.68% for 2026 [6].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is exploring a second growth curve through diversified strategies and deep integration of digital intelligence systems [1][9] - The company has faced short-term performance pressure due to multiple factors, but the Torch project has improved gross margins [6] - The company is focusing on expanding its store network and optimizing its layout, with steady growth in its franchise business [7] Financial Performance Summary - For the year 2024, the company reported revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 22.36 billion, 519 million, and 496 million yuan respectively, showing a year-on-year change of -0.36%, -44.13%, and -41.18% [5] - The company announced a profit distribution plan, proposing a cash dividend of 0.8 yuan per 10 shares [5] - In Q1 2025, the company achieved revenue, net profit attributable to shareholders, and net profit excluding non-recurring items of 5.43 billion, 251 million, and 243 million yuan respectively, with year-on-year changes of -1.88%, -21.98%, and -21.59% [5] Operational Insights - The company has increased its store count to 15,277 by the end of 2024, with a focus on expanding in 11 key provinces [7] - The company has optimized its store layout by closing underperforming stores and increasing the proportion of franchise operations [7] - The company is enhancing its digital intelligence system to improve operational efficiency and cost optimization [8] Growth Projections - The company is expected to achieve long-term stable growth driven by its franchise business and the Torch project, which has effectively improved gross margins [9] - The revenue forecast for 2025 is set at 23.81 billion yuan, with a growth rate of 6.50% [10] - The net profit forecast for 2025 is 702 million yuan, reflecting a growth rate of 35.29% compared to 2024 [10] Valuation Metrics - The current price corresponds to a P/E ratio of 20 for 2025, 17 for 2026, and 15 for 2027 [9] - The company’s estimated P/B ratio is projected to be 2.0 in 2025, 1.9 in 2026, and 1.8 in 2027 [10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative increase in stock price of over 20% compared to the benchmark index within the next six months [10][16]. Core Insights - The company plans to acquire stakes in four subsidiaries from its controlling shareholder, China Gold Group, which is expected to enhance its gold production capacity and profitability [3][10]. - The projected net profit for the company is expected to grow significantly, with estimates of 47.45 billion, 62.45 billion, and 73.51 billion for the years 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 40.13%, 31.61%, and 17.71% [10][12]. Company Overview - The latest closing price of the company's stock is 13.90 yuan, with a total market capitalization of 674 billion yuan [2]. - The company has a total share capital of 4.847 billion shares, with a debt-to-asset ratio of 41.5% and a price-to-earnings ratio of 19.86 [2]. Acquisition Details - The company intends to acquire a 49.33625% stake in Inner Mongolia Jintao, which produced 1.37 tons of gold in 2024, and has total audited assets of 747 million yuan [4]. - The acquisition of an 80% stake in Hebei Dabaoyang, which produced 0.28 tons of gold in 2024, is also planned, with total audited assets of 235 million yuan [5]. - Additionally, the company aims to acquire a 70% stake in Liaoning Tianli, which produced 1.23 tons of refined gold in 2024, with total audited assets of 490 million yuan [6]. - Lastly, a 70% stake in Liaoning Jinfeng, which produced 0.28 tons of gold in 2024, is included in the acquisition plan, with total audited assets of 149 million yuan [9]. Financial Projections - The company’s revenue is projected to grow from 65.56 billion yuan in 2024 to 77.40 billion yuan in 2027, with a compound annual growth rate of approximately 6.88% [12][15]. - The expected earnings per share (EPS) are forecasted to increase from 0.70 yuan in 2024 to 1.52 yuan in 2027 [12][15]. - The price-to-earnings ratio is anticipated to decrease from 19.90 in 2024 to 9.17 by 2027, indicating improved valuation as earnings grow [12][15].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [7] Core Views - The company is expected to achieve revenue growth driven by new product launches, international expansion, and innovation in drug development. The anesthetic pipeline continues to evolve, with several high-barrier products approved for market entry, which is anticipated to enhance the company's competitive edge in the anesthetic and analgesic sectors [10][12] Summary by Relevant Sections Growth Capability - In 2024, the company's chemical preparations generated revenue of 1.077 billion yuan, a year-over-year increase of 22.25%. Chemical raw materials achieved revenue of 121 million yuan, up 28.65%. CMO/CDMO services saw revenue of 65 million yuan, a significant increase of 111.59%. The company has undertaken 23 CMO/CDMO projects, indicating strong growth potential from new product launches and international business expansion [2] - The company plans to launch at least 10 generic drug products and submit at least 10 new product applications in 2025, which is expected to contribute to revenue growth in the coming years [2] Internationalization of Formulations - The company received FDA approval for its Nicardipine Hydrochloride Injection in September 2024, marking its first shipment to the U.S. market. The company is gradually expanding its international product offerings, with several ANDA applications submitted for various products [3] Competitive Position in Anesthesia - As of 2024, the company has launched 16 products in the anesthetic and analgesic fields, with over 20 in development. The market share for key products is strong, with the company's Nalmefene Hydrochloride Injection holding a 61.73% market share. Newly approved high-barrier products are expected to drive revenue growth [4] - The company is advancing its high-end generic drugs, improved new drugs, and innovative drugs in the anesthetic and analgesic sectors, which will help establish its brand and enhance core competitiveness [4] Innovation and R&D Acceleration - The company is accelerating its transition from generic to innovative drug development, with R&D expenditures exceeding 20% of revenue in 2024. Investment in innovative drugs accounts for nearly 30% of R&D spending, indicating a strong commitment to innovation [5] Financial Performance - In 2024, the company achieved revenue of 1.35 billion yuan, a year-over-year increase of 20.82%, with a net profit of 238 million yuan, up 5.15%. The net profit margin after excluding stock incentive expenses showed a stable growth trend [10][12] - The overall gross margin for 2024 was 74.93%, a decrease of 5.08 percentage points, primarily due to declines in the gross margins of technical services, CMO/CDMO, and raw materials [11] Earnings Forecast and Valuation - The company is projected to achieve EPS of 1.56, 1.83, and 2.19 yuan per share for 2025, 2026, and 2027, respectively. The current closing price corresponds to a PE ratio of 22 times for 2025 [12]

Investment Rating - The investment rating for the company is "Buy" indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [22]. Core Views - The company's performance is under short-term pressure, with expectations for recovery driven by overseas expansion and domestic market recovery [2][4]. - The company reported a revenue of 4.471 billion (up 0.62% year-on-year) and a net profit of 1.194 billion (down 1.89% year-on-year) for 2024, while Q1 2025 saw a revenue of 996 million (down 8.56% year-on-year) and a net profit of 270 million (down 16.76% year-on-year) [3][5]. - The company is actively responding to centralized procurement impacts, with expectations for recovery in the second quarter of 2026 [5]. Financial Performance - In 2024, the company achieved revenue of 25.56 billion in immunodiagnostics (up 2.91% year-on-year), while biochemical testing revenue was 2.22 billion (down 11.21% year-on-year), and microbiological testing revenue was 3.61 billion (up 11.48% year-on-year) [5]. - The overseas business generated revenue of 284 million in 2024 (up 36.25% year-on-year), indicating strong growth potential [6]. - The company maintained stable expense ratios, with a sales expense ratio of 17.2%, management expense ratio of 4.7%, and R&D expense ratio of 16.4% (up 1.6 percentage points) [6]. Product Development and Market Position - The company launched new products including the AutoChem B2000 and B8000 series of fully automated biochemical analyzers, and the Autof T series of microbial mass spectrometry detection systems [6]. - In the NGS segment, the company’s subsidiary successfully launched three gene sequencers and an automated pathogen analysis system, with further products in trial production [6]. Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025-2027 is 2.2, 2.6, and 3.0 respectively, with corresponding price-to-earnings (PE) ratios of 17, 15, and 13 [7]. - The company is recognized as a pioneer in the domestic IVD platform, with increased R&D investment expected to enhance competitiveness [7].